




Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy
Across Body Mass Index in RE-DUAL PCI
De Caterina, Raffaele; Procopio, Antonio; Lopez Sendon, José-Luis; Raev, Dimitar; Mehta,
Shamir R; Opolski, Grzegorz; Oldgren, Jonas; Steg, Philippe Gabriel; Hohnloser, Stefan H;
Lip, Gregory Y H; Kimura, Takeshi; Kleine, Eva; Ten Berg, Jurriën M; Bhatt, Deepak L;
Miede, Corinna; Nordaby, Matias; Cannon, Christopher P; RE-DUAL PCI Steering Committee
and Investigators
Published in:
American Journal of Medicine







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
De Caterina, R., Procopio, A., Lopez Sendon, J-L., Raev, D., Mehta, S. R., Opolski, G., Oldgren, J., Steg, P. G.,
Hohnloser, S. H., Lip, G. Y. H., Kimura, T., Kleine, E., Ten Berg, J. M., Bhatt, D. L., Miede, C., Nordaby, M.,
Cannon, C. P., & RE-DUAL PCI Steering Committee and Investigators (2020). Comparison of Dabigatran Plus a
P2Y
12
 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. American
Journal of Medicine, 133(11), 1302-1312. https://doi.org/10.1016/j.amjmed.2020.03.045
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
TAGGEDENDCLINICAL RESEARCH STUDY
TaggedFigure TaggedEndTaggedH1Comparison of Dabigatran Plus a P2Y12 Inhibitor
With Warfarin-Based Triple Therapy Across Body
Mass Index in RE-DUAL PCITaggedEnd
TaggedPRaffaele De Caterina, MD, PhD,a Antonio Procopio, MD,b Jose-Luis Lopez Sendon, MD,c Dimitar Raev, MD, PhD, DSc,d
Shamir R. Mehta, MD, MSc,e Grzegorz Opolski, MD, PhD,f Jonas Oldgren, MD, PhD,g Philippe Gabriel Steg, MD,h
Stefan H. Hohnloser, MD,i Gregory Y.H. Lip, MD,j,k Takeshi Kimura, MD, PhD,l Eva Kleine, MSc,m
Jurri€en M. ten Berg, MD,n Deepak L. Bhatt, MD, MPH,o Corinna Miede, MSc,p Matias Nordaby, MD,m
Christopher P. Cannon, MDo TaggedEnd, on behalf of the RE-DUAL PCI Steering Committee and Investigators
TaggedP
aDepartment of Cardiology, University of Pisa, Pisa, Italy; bDepartment of Cardiology and Center of Excellence on Aging, G. d’Annunzio University,
Chieti, Italy; cCardiology, University Hospital La Paz, UAM, CIBER-CV, IdiPaz, Madrid, Spain; dClinic of Internal Medicine, University
Hospital “St. Anna,” Sofia, Bulgaria; eDepartment of Cardiology, McMaster University, Hamilton, Ontario, Canada; fDepartment of Cardiology,
Medical University of Warsaw, Warsaw, Poland; gUppsala Clinical Research Center and Department of Medical Sciences, Uppsala University,
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BACKGROUND: Body mass index (BMI) affects drug levels of nonvitamin K antagonist oral anticoagu-
lants. We sought to assess whether BMI affected outcomes in the RE-DUAL PCI trial.
METHODS: RE-DUAL PCI (NCT02164864) evaluated the safety and efficacy of a dual-antithrombotic-
therapy regimen using dabigatran (110 mg or 150 mg twice daily and a P2Y12 platelet antagonist) in com-
parison with triple therapy of warfarin, aspirin, and a P2Y12 platelet inhibitor in 2725 patients with atrial
fibrillation who had undergone percutaneous coronary intervention (PCI). We compared the risk of first
International Society on Thrombosis and Haemostasis (ISTH)-defined major or clinically relevant nonma-
jor bleeding events (primary endpoint) and the composite of death, myocardial infarction, stroke, systemic
embolism, or unplanned revascularization (main efficacy endpoint) in relation to baseline BMI.
RESULTS: Median (range) BMI was 28.1 (14-66) kg/m2. Dabigatran dual therapy versus warfarin triple
therapy had relevantly and similarly lower rates of bleeding at both 110 mg and 150 mg twice-daily doses,
irrespective of BMI. Thromboembolic event rates appeared consistent across categories of BMI, including
those <25 and ≥35 kg/m2 (P for interaction: 0.806 and 0.279, respectively).
CONCLUSIONS: The reduction in bleeding with dabigatran dual therapy compared with warfarin triple ther-
apy in patients here evaluated appears consistent across BMI categories.
 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)  The American Journal of Medicine (2020)
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TaggedEndDe Caterina et al BMI and Events in RE-DUAL PCI 1303TAGGEDH1INTRODUCTION TAGGEDEND coronary artery disease with a bare-metal or drug-eluting stent
TaggedP he four nonvitamin K antagonist oral anticoagulants
(NOACs) currently available for long-term use in atrial fibril-
lation and venous thromboembolism—dabigatran etexilate
(dabigatran), rivaroxaban, apixaban, and edoxaban1,2—exert
anticoagulant effects related to their plasma concentrations.3-
6 Because the distribution volume of NOACs is related—atCLINICAL SIGNIFICANCE
TaggedEndTaggedP The current subanalysis of the RE-DUAL
PCI study assessed the impact of body
mass index (BMI) on the treatment
effects of dabigatran dual therapy
compared with warfarin triple therapy. TaggedEnd
TaggedEndTaggedP The benefit of dabigatran dual therapy
compared with warfarin triple therapy
in patients with atrial fibrillation after
percutaneous coronary intervention was
consistent regardless of BMI, including
patients with low (<25 kg/m2) and
high (≥35 kg/m2) BMI.TaggedEndleast in part—to body weight (and
its correlates, including body mass
index [BMI]), extremes in BMI or
body weight may affect their effi-
cacy or safety.7-10 Efficacy and
safety of NOACs are also affected
by concomitant antiplatelet ther-
apy,11 as in patients having both an
indication to anticoagulation because
of atrial fibrillation or venous throm-
boembolism and also requiring coro-
nary stenting.12-14 Patients are here
exposed to a high risk of both throm-
botic events for the possible occur-
rence of stent thrombosis or
recurrent acute coronary syndrome
and of bleeding due to the antithrom-
botic drug combination.14,15 Data on
efficacy and safety of the NOACs insuch conditions, different from the setting of atrial fibrillation
without recent stenting,16 are limited, and even more so in
extremes of BMI.8TaggedEnd
TaggedP he Randomized Evaluation of Dual Antithrombotic
Therapy with Dabigatran versus Triple Therapy with Warfa-
rin in Patients with Nonvalvular Atrial Fibrillation Undergo-
ing Percutaneous Coronary Intervention (RE-DUAL PCI)
trial was a randomized controlled trial with main objectives
of assessing safety and gathering preliminary efficacy data
for 2 regimens of dual antithrombotic therapy with dabiga-
tran twice daily (BID) plus a P2Y12 inhibitor compared with
the standard triple-antithrombotic therapy combination of
warfarin plus a P2Y12 inhibitor plus aspirin ≤100 mg once
daily (warfarin triple therapy) in patients with atrial fibrilla-
tion and receiving coronary stenting.17,18 This trial thus pro-
vides a unique opportunity to explore efficacy or safety of
dabigatran dual therapy across classes of BMI in conditions
with a high risk of thrombotic and bleeding events.TaggedEnd
TaggedPHere we report on the safety and efficacy of the dabigatran
dual-therapy regimens examined against warfarin triple ther-
apy in the classes of BMI of patients included in the trial.TaggedEndTAGGEDH1METHODS TAGGEDEND
TaggedH2RE-DUAL PCI Study Population and Design TaggedEnd
TaggedP he RE-DUAL PCI trial design has been previously pub-
lished.17 Here men and women ≥18 years of age were eligible
for inclusion in the trial if they had atrial fibrillation poten-
tially treatable long-term with one of the NOACs and had suc-
cessfully undergone PCI in acute coronary syndrome or stableimplantation within the previous 120 hours. Patients had
received standard an antithrombotic treatment for the PCI pro-
cedure. After PCI, eligible patients were randomly assigned in
a 1:1:1 ratio to receive 1 of 3 treatments: dual therapy with
dabigatran 110 mg BID plus either clopidogrel or ticagrelor
(dabigatran 110 mg dual-therapy group), dual therapy withdabigatran 150 mg BID plus either
clopidogrel or ticagrelor (dabigatran
150 mg dual-therapy group), or triple
therapy with warfarin plus aspirin
(≤100 mg once daily) and either clo-
pidogrel or ticagrelor (warfarin triple
therapy). Patients’ follow-up was per-
formed every 3 months. The trial con-
tinued until all the patients had a
minimum of 6 months of follow-up
and the target number of endpoint
events was anticipated to be reached.TaggedEnd
TaggedH2Endpoints TaggedEnd
TaggedPAs in the trial,17,18 the primary end-
point here was the first major bleed-
ing event or clinically relevant
nonmajor bleeding event as defined
by the International Society onThrombosis and Haemostasis (ISTH) criteria in a time-to-
event analysis. A main secondary—efficacy—endpoint was
a composite of time-to-death or time-to-first thromboembolic
event (death and thromboembolic event: myocardial infarc-
tion, stroke, or systemic embolism) or unplanned revasculari-
zation (PCI or coronary artery bypass grafting). Other
secondary endpoints included the combination of death and
thromboembolic event alone, as well as individual thrombo-
embolic events and definite stent thrombosis. Clinical end-
point events were adjudicated by an independent committee
unaware of treatment assignments.TaggedEnd
TaggedH2Clustering of Patients According to BMITaggedEnd
TaggedPWe divided the patient population into 4 prespecified dis-
crete accepted categories of BMI:19 <25 kg/m2 body sur-
face area (BSA; normal weight and underweight); 25 to
<30 kg/m2 BSA (overweight); 30 to <35 kg/m2 BSA (Class
I moderate obesity); and ≥35 kg/m2 BSA (severe obesity).
BMI categories were not based on equal numbers of
patients per category.TaggedEnd
TaggedH2Statistical Analyses TaggedEnd
TaggedPWe summarized baseline characteristics descriptively by
BMI subgroup. For the comparison of dabigatran 110 mg
dual therapy versus warfarin triple therapy within the BMI
subgroups, we applied Cox proportional hazard regression
models stratified by age (nonelderly vs elderly [<80 years
vs ≥80 years; <70 years vs ≥70 years in Japan]). We calcu-
lated hazard ratios (HRs) and 2-sided 95% Wald confidence
intervals (CIs) for HRs resulting from Cox proportional
TaggedEnd1304 The American Journal of Medicine, Vol 133, No 11, November 2020hazard models. For the comparison of dabigatran 150 mg
dual therapy compared with warfarin triple therapy, we
applied unstratified Cox proportional hazard regression
models. We provide exploratory treatment-by-subgroup
interaction P values resulting from Cox proportional hazard
regression models. TaggedEnd
TaggedP o further investigate BMI effects on outcomes, we
compared the risk of the primary safety endpoint and of the
main composite efficacy endpoint with a multivariable Cox
proportional hazard regression model that included treat-
ment and BMI as a continuous variable, as well as the inter-
action between treatment and BMI. The resulting HRs and
CIs comparing dabigatran dual therapy with warfarin triple
therapy for varying values of BMI were visualized via inter-
action plots. For the comparison of dabigatran 110 mg ver-
sus warfarin triple therapy, we stratified the multivariable
model by age. TaggedEndTAGGEDH1RESULTS TAGGEDEND
TaggedH2Patient Distribution According to Classes of BMITaggedEnd
TaggedPDistributions of patients enrolled in the trial according to
classes of BMI are reported in Table 1. Most patients were
in the middle categories, with the class of BMI 25 to <30
kg/m2 BSA being the most represented (n = 677 dabigatran




Age (years) 73.3 § 8.2
Age ≥80 (years), n (%) 145 (23.5)
Female sex, n (%) 171 (27.7)
Creatinine clearance,a mL/min 61.7 § 19.4
BMI (kg/m2) 22.9 § 1.8
Weight, kg 66.0 § 9.3
Prior MI, n (%) 144 (23.3)
Prior PCI,b n (%) 198 (32.0)
Indication for PCI,b n (%)
ACS 331 (53.6)
Elective PCI (non-ACS) 287 (46.4)




Previous stroke,b n (%) 55 (8.9)
CHA2DS2VASc score 3.7 § 1.5
CHA2DS2VASc score >2, n (%) 468 (75.7)
Modified HASBLED score 2.7 § 0.7
Modified HASBLED score ≥3, n (%) 409 (66.2)
All values are means § SD unless stated otherwise.
aData missing from 50 patients in BMI <25 kg/m2; 89 patients in BMI 25 to<30
bData missing from 1 patient in BMI 25 to <30 kg/m2. BMI data were missing
ACS = acute coronary syndrome; BMI = body mass index; MI = myocardial infarcclasses was clearly skewed toward the overall mean val-
ues, but there were extreme values of either very low
(16 kg/m2) or very high (66 kg/m2) BMI. There were
trends to lower age and higher creatinine clearance in clas-
ses of higher BMI. TaggedEndTaggedH2Safety and Efficacy Outcomes According to
Classes of BMI TaggedEnd
TaggedPSafety outcomes in terms of the primary safety endpoint by
BMI categories are shown in Figure 1. TaggedEnd
TaggedPWith regard to the primary safety endpoint, there was no
evidence of interaction between BMI and treatment for
either 110 mg dabigatran dual therapy versus warfarin triple
therapy or 150 mg dabigatran dual therapy versus warfarin
triple therapy. In particular, the risk of a major bleeding
event or clinically relevant nonmajor bleeding event was
similar in the critical category of BMI <25 kg/m2
(Figure 1). The total number of patients in the lowest BMI
category was small, and we therefore refrained from any
interpretation of data in this category.TaggedEnd
TaggedPEfficacy outcomes according to BMI categories are
shown in Figure 2. Outcomes for the other secondary effi-
cacy endpoints of death and thromboembolic event, as well
as for the one combining the individual thromboembolic
events and definite stent thrombosis, are shown in Tables 2







71.3 § 8.6 69.6 § 8.4 66.7 § 8.3
176 (15.8) 75 (11.3) 17 (5.2)
235 (21.1) 141 (21.2) 106 (32.5)
73.2 § 22.9 87.6 § 29.4 107.1 § 39.7
27.3 § 1.4 32.1 § 1.4 38.9 § 4.3
80.1 § 9.7 94.4 § 11.0 111.2 § 17.3
289 (26.0) 180 (27.1) 86 (26.4)
373 (33.5) 227 (34.2) 113 (34.7)
566 (50.9) 330 (49.7) 146 (44.8)
546 (49.1) 334 (50.3) 180 (55.2)
562 (50.5) 310 (46.7) 141 (43.3)
174 (15.6) 128 (19.3) 63 (19.3)
376 (33.8) 225 (33.9) 122 (37.4)
94 (8.4) 59 (8.9) 18 (5.5)
3.6 § 1.6 3.6 § 1.6 3.6 § 1.5
838 (75.3) 497 (74.8) 248 (76.1)
2.7 § 0.7 2.7 § 0.7 2.6 § 0.7
753 (67.7) 433 (65.2) 184 (56.4)
kg/m2; 58 patients in BMI 30 to<35 kg/m2; 34 patients in BMI≥35 kg/m2.
from 4 patients.
tion; PCI = percutaneous coronary intervention; SD = standard deviation.
TaggedEnd TaggedFigure
Figure 1 Primary safety endpoint (ISTH MBEs or CRNMBEs according to the study charter definitions) by BMI discrete
categories. HRs and 95% CIs from Cox proportional hazard models; (A) stratified by age (elderly vs nonelderly) are plotted
for the comparison of dabigatran 110-mg dual therapy versus warfarin triple therapy in the upper panel, and (B) from
unstratified Cox proportional hazard models for the comparison of dabigatran 150-mg dual therapy versus warfarin triple
therapy in the lower panel (excluding elderly patients outside the United States ≥80 years of age [≥70 years of age in
Japan]).
BMI = body mass index; CI = confidence interval; CRNMBE = clinically relevant nonmajor bleeding event; HR = hazard
ratio; ISTH = International Society on Thrombosis and Haemostasis; MBE =major bleeding event.
TaggedEnd
TaggedEndDe Caterina et al BMI and Events in RE-DUAL PCI 1305TaggedPWith regard to the main efficacy endpoint, we found no
evidence of interaction between BMI and treatment with
either 110 mg dabigatran dual therapy versus warfarin triple
therapy or 150 mg dabigatran dual therapy versus warfarin
triple therapy. TaggedEndTaggedH2Safety and Efficacy Outcomes According to BMI
Treated as a Continuous Variable TaggedEnd
TaggedPInteraction plots for BMI and primary safety and main effi-
cacy endpoints, displaying the HRs and 95% CIs in the
comparison of dabigatran 110 mg dual therapy versus war-
farin triple therapy and dabigatran 150 mg dual therapy ver-
sus warfarin triple therapy are shown in Figures 3 and 4,
respectively. As to the primary safety endpoint, the line of
the HR was here always below the warfarin triple therapy
reference line throughout all values of BMI for dabigatran
110 mg dual therapy, although with wider CIs for the
extreme BMI values (interaction P value = 0.2370), and
below the reference line down to approximately 20 kg/m2,
with CIs not overlapping the warfarin triple-therapy
reference line down to approximately 25 kg/m2 for the
dabigatran 150 mg dual-therapy dose (interactionP value = 0.1491). As to the main efficacy endpoint, CIs
included the warfarin triple-therapy reference line through-
out all BMI values for the dabigatran 110 mg dual-therapy
dose; and the HR line was below the warfarin triple-therapy
reference line for the dabigatran 150 mg dual-therapy dose
for most BMI values, suggesting at least consistent efficacy
across BMI groups (interaction P values = 0.6578 and
0.3434, respectively). TaggedEndTAGGEDH1 ISCUSSION TAGGEDEND
TaggedP his analysis of RE-DUAL PCI shows that the relative
safety and efficacy of dabigatran 150 mg or 110 mg dual
therapy compared with warfarin triple therapy are largely
preserved in different categories of BMI. These data are
quite reassuring for the possible use of the dual-therapy
combination in most categories of patients with an indica-
tion for anticoagulation because of atrial fibrillation and a
recent stenting demanding antiplatelet therapy to prevent
stent thrombosis.14 TaggedEnd
TaggedPSafety and efficacy of the NOACs in lower and higher
levels of BMI are, in general, of concern, because of the
standard dosing of the NOACs without titration, contrary to
TaggedEnd TaggedFigure
Figure 2 Main efficacy endpoint (DTE or unplanned revascularization according to the study charter definitions) by BMI
discrete categories. Thromboembolic events were myocardial infarction, stroke, or systemic embolism (acute vascular
occlusion of the extremities or any organ). Unplanned revascularization was percutaneous coronary intervention or coro-
nary artery bypass grafting. Statistics as in Figure 1.
BMI = body mass index; CI = confidence interval; DTE = death and thromboembolic event; HR = hazard ratio.
TaggedEnd
TaggedEnd1306 The American Journal of Medicine, Vol 133, No 11, November 2020what occurs in the case of warfarin. This potentially implies
excess bleeding in patients with low BMI and lack of effi-
cacy (ie, an excess of thromboembolic events) in patients
with high BMI.8,9 By dividing patient categories according
to classes of BMI, we did not find evidence of any signifi-
cant interactions between BMI subgroup and treatment
with regard to any of the evaluated safety or efficacy
endpoints. We devoted particular attention to safety
(bleeding events) in patients with low to normal BMI
(<25 kg/m2) and to efficacy (thromboembolic events,
including stent thrombosis) in patients with very high BMI
(≥35 kg/m2). We found largely similar results when treating
BMI as a continuous variable. TaggedEnd
TaggedPIn the absence of more robust evidence deriving from
much larger—but not forthcoming—trials, the similar
occurrence of ischemic events in RE-DUAL PCI (espe-
cially with dabigatran 150 mg dual therapy), together with
the superior safety on bleeding with dabigatran dual therapy
compared with warfarin triple therapy, are strong argu-
ments for preferring a dual-therapy regimen including dabi-
gatran and a P2Y12 inhibitor over the classical triple-
therapy arm with warfarin, aspirin, and clopidogrel. We
now extend these findings in observing consistent results
for both safety and efficacy in even lower and higher levels
of BMI, with reduced bleeding risk preserved also withBMI <25 kg/m2; similar efficacy was also shown for a BMI
≥35 kg/m2 class. This latter patient category also had a
higher value of creatinine clearance compared with lower
BMI categories. Because dabigatran is largely excreted
through the kidneys,20 one could fear a dangerous decrease
in plasma concentrations of the active drug in such patient
categories, through a combination of increased distribution
volume and higher renal excretion. This was apparently
not the case in the light of our data. This would support
the possibility of adopting the dual-therapy regimens with
dabigatran and a P2Y12 inhibitor especially in situations in
which bleeding is the major concern, such as low BMI, or
where lack of protection from ischemic events is the major
concern, such as in the setting of very obese patients. In
this latter setting, a dabigatran 150 mg dual-therapy regi-
men appears a reasonable alternative to warfarin triple
therapy.TaggedEnd
TaggedPWe have limited data on outcomes in patients with
extreme BMIs; therefore, our data cannot change any rec-
ommendations on use in those with BMI >40.8 TaggedEndTAGGEDH1 ATA-SHARING STATEMENT TAGGEDEND
TaggedP o ensure independent interpretation of clinical study
results, Boehringer Ingelheim grants all external authors
TaggedEnd Table 2 Safety and Efficacy Outcomes According to BMI Categories in the Dabigatran 110-mg Dual Therapy Versus Warfarin Triple Therapy Comparisons
BMI Category (kg/m2)




























Major bleeding event - Clinically relevant nonmajor bleeding
Events, no. (%) 54 (23.1) 77 (34.8) 59 (15.9) 118 (27.1) 27 (10.4) 43 (20.4) 11 (9.8) 25 (22.3)
HR (95% CI) 0.59 (0.42-0.83) 0.54 (0.39-0.74) 0.46 (0.28-0.75) 0.38 (0.19-0.77)
Interaction P value = 0.6708
Death and thromboembolic event or unplanned revascularization
Events, no. (%) 38 (16.2) 28 (12.7) 60 (16.1) 68 (15.6) 37(14.2) 23 (10.9) 13 (11.6) 12 (10.7)
HR (95% CI) 1.34 (0.82-2.18) 1.01 (0.72-1.44) 1.27 (0.75-2.14) 1.04 (0.48-2.29)
Interaction P value = 0.8057
Death and thromboembolic event
Events, no. (%) 27 (11.5) 16 (7.2) 43 (11.6) 43 (9.9) 26 (10.0) 14 (6.6) 11 (9.8) 10 (8.9)
HR (95% CI) 1.66 (0.89-3.09) 1.16 (0.76-1.77) 1.50 (0.78-2.87) 1.06 (0.45-2.51)
Interaction P value = 0.7674
Unplanned revascularization
Events, no. (%) 21 (9.0) 14 (6.3) 30 (8.1) 37 (8.5) 19 (7.3) 13 (6.2) 6 (5.4) 5 (4.5)
HR (95% CI) 1.45 (0.74-2.87) 0.93 (0.57-1.51) 1.11 (0.55-2.26) 1.14 (0.35-3.75)
Interaction P value = 0.7608
All-cause death - stroke - MI
Events, no. (%) 26 (11.1) 16 (7.2) 43 (11.6) 40 (9.2) 26 (10.0) 14 (6.6) 11 (9.8) 10 (8.9)
HR (95% CI) 1.59 (0.85-2.96) 1.25 (0.81-1.93) 1.50 (0.78-2.89) 1.06 (0.45-2.51)
Interaction P value = 0.8739
MI
Events, no. (%) 13 (5.6) 6 (2.7) 17 (4.6) 14 (3.2) 10 (3.8) 6 (2.8) 4 (3.6) 3 (2.7)
HR (95% CI) 2.08 (0.79-5.48) 1.41 (0.70-2.87) 1.27 (0.46-3.51) 1.26 (0.28-5.63)
Interaction P value = 0.8996
Stroke
Events, no. (%) 3 (1.3) 6 (2.7) 3 (0.8) 5 (1.1) 8 (3.1) 2 (0.9) 2 (1.8) 0
HR (95% CI) 0.49 (0.12-1.95) 0.68 (0.16-2.83) 3.45 (0.73-16.35) n.d.
Interaction P value = 0.2889
Definite stent thrombosis
Events, no. (%) 5 (2.1) 3 (1.4) 5 (1.3) 3 (0.7) 4 (1.5) 1 (0.5) 1 (0.9) 1 (0.9)
HR (95% CI) 1.61 (0.38-6.74) 1.91 (0.46-8.01) 3.44 (0.38-30.91) 0.98 (0.06-15.74)
Interaction P value = 0.9216
HRs and 95% CIs from Cox proportional hazard models; stratified by age (elderly vs nonelderly). n.d.: at least 1 treatment group has 0 events and HR is not given. BMI data were missing from 4 patients. Interac-
tion P value between treatment and subgroup.


























TaggedEnd Table 3 Safety and Efficacy Outcomes According to BMI Categories in the Dabigatran 150-mg Dual Therapy Versus Warfarin Triple Therapy Comparisons
BMI Category (kg/m2)

























Major bleeding event - Clinically relevant nonmajor bleeding
Events, no. (%) 41 (25.2) 49 (32.9) 69 (22.6) 85 (25.4) 29 (15.0) 36 (20.6) 15 (14.7) 25 (23.8)
HR (95% CI) 0.70 (0.46-1.06) 0.83 (0.61-1.15) 0.67 (0.41-1.09) 0.51 (0.27-0.96)
Interaction P value = 0.5379
Death and thromboembolic event or unplanned revascularization
Events, no. (%) 22 (13.5) 17 (11.4) 31 (10.2) 49 (14.7) 28 (14.5) 20 (11.4) 9 (8.8) 12 (11.4)
HR (95% CI) 1.22 (0.65-2.29) 0.68 (0.43-1.06) 1.23 (0.69-2.18) 0.70 (0.29-1.65)
Interaction P value = 0.2788
Death and thromboembolic event
Events, no. (%) 15 (9.2) 9 (6.0) 19 (6.2) 29 (8.7) 20 (10.4) 12 (6.9) 6 (5.9) 10 (9.5)
HR (95% CI) 1.56 (0.68-3.56) 0.70 (0.39-1.26) 1.47 (0.72-3.00) 0.56 (0.20-1.54)
Interaction P value = 0.1925
Unplanned revascularization
Events, no. (%) 12 (7.4) 8 (5.4) 20 (6.6) 27 (8.1) 15 (7.8) 12 (6.9) 4 (3.9) 5 (4.8)
HR (95% CI) 1.43 (0.58-3.50) 0.79 (0.45-1.42) 1.11 (0.52-2.37) 0.75 (0.20-2.78)
Interaction P value = 0.7005
All-cause death - stroke - MI
Events, no. (%) 15 (9.2) 9 (6.0) 19 (6.2) 26 (7.8) 20 (10.4) 12 (6.9) 6 (5.9) 10 (9.5)
HR (95% CI) 1.56 (0.68-3.56) 0.79 (0.44-1.43) 1.47 (0.72-3.00) 0.56 (0.20-1-54)
Interaction P value = 0.2623
MI
Events, no. (%) 6 (3.7) 4 (2.7) 11 (3.6) 9 (2.7) 7 (3.6) 6 (3.4) 2 (2.0) 3 (2.9)
HR (95% CI) 1.38 (0.39-4.90) 1.32 (0.55-3.18) 1.04 (0.35-3.08) 0.64 (0.11-3.84)
Interaction P value =0 .8912
Stroke
Events, no. (%) 2 (1.2) 5 (3.4) 2 (0.7) 2 (0.6) 5 (2.6) 1 (0.6) 0 0
HR (95% CI) 0.38 (0.07-1.96) 1.07 (0.15-7.57) 4.32 (0.50-36.97) n.d.
Interaction P value = .03620
Definite stent thrombosis
Events, no. (%) 1 (0.6) 3 (2.0) 3 (1.0) 2 (0.6) 3 (1.6) 1 (0.6) 0 1 (1.0)
HR (95% CI) 0.30 (0.03-2.90) 1.62 (0.27-9.68) 2.71 (0.28-26.01) n.d.
Interaction P value = 0.5673
For the comparison with dabigatran 150-mg dual therapy, elderly patients outside the United States ≥80 years of age (≥70 years of age in Japan) are excluded. HRs and 95% CIs from unstratified Cox propor-
tional hazard models. n.d.: at least 1 treatment group has 0 events and HR is not given. BMI data were missing from 1 patient. Interaction P value between treatment and subgroup.










































Figure 3 Primary safety endpoint (ISTH MBE and CRNMBE): interaction plot for varying values of
BMI as a continuous variable. Interaction plot showing the HRs and corresponding 95% CI comparing
the risk of adjudicated MBEs or CRNMBEs (RE-DUAL PCI primary safety endpoint) in patients
treated with dabigatran 110 mg twice daily plus the P2Y12 inhibitor (dabigatran dual therapy) versus tri-
ple antithrombotic therapy with aspirin, the P2Y12 inhibitor, and warfarin (warfarin triple therapy) for
varying values of BMI. HRs (solid lines) and Wald 95% CIs from stratified Cox proportional hazard
model including treatment, continuous variable BMI, and the interaction term of treatment by BMI
(upper panel); and comparing dabigatran 150-mg dual therapy versus warfarin triple therapy (lower
panel). For the comparison with dabigatran 150-mg dual therapy, elderly patients outside the United
States ≥80 years of age (≥70 years of age in Japan) are excluded and HRs and 95% CIs are from an
unstratified Cox proportional hazard model (lower panel). For each panel the horizontal dashed line
depicts the reference line for a HR of 1.
BMI = body mass index; CI = confidence interval; CRNMBE = clinically relevant nonmajor bleeding
event; HR = hazard ratio; ISTH = International Society on Thrombosis and Haemostasis; MBE =major
bleeding event; RE-DUAL PCI = Randomized Evaluation of Dual Antithrombotic Therapy with
Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Under-
going Percutaneous Coronary Intervention trial.
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TaggedEnd TaggedFigure
Figure 4 Main efficacy endpoint (DTE and unplanned revascularization): interaction plot for varying
values of BMI as a continuous variable. Interaction plot showing the HRs and corresponding 95%
CI comparing the risk of adjudicated death and thrombotic events/unplanned revascularization
(REDUAL PCI main efficacy endpoint) in patients treated with dabigatran 110 mg twice daily plus the
P2Y12 inhibitor (dabigatran dual therapy) versus triple antithrombotic therapy with aspirin, the P2Y12
inhibitor and warfarin (warfarin triple therapy) for varying values of BMI. HRs (solid lines) and Wald
95% CIs from stratified Cox proportional hazard model including treatment, continuous variable BMI,
and the interaction term of treatment by BMI (upper panel); and comparing dabigatran 150-mg dual
therapy versus warfarin triple therapy (lower panel). For the comparison with dabigatran 150-mg dual
therapy, elderly patients outside the United States ≥80 years of age (≥70 years of age in Japan) are
excluded, and HRs and 95% CIs are from an unstratified Cox proportional hazard model (lower panel).
For each panel the horizontal dashed line depicts the reference line for a HR of 1.
BMI = body mass index; CI = confidence interval; DTE = death and thromboembolic event; HR = haz-
ard ratio; RE-DUAL PCI = Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran
versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percu-
taneous Coronary Intervention trial.
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